Replies to post #211994 on Biotech Values

[Whalatane]

Dew ...I think this is good for AMRN. Amarins Vascepa lowers hsCRP and seems to have a similar method of action ...and at significantly lower cost .
JMO
Kiwi

[genisi]

Ilaris, which is currently approved for orphan indications and sells about $250 per annum, will likely become one of the pharma industry’s biggest-selling drugs as a consequence of these new data

Good for REGN too.